Evidence map›Paper›PMID 38473418›Full record

ArticleCancers2024

Sonographic Measurements of Rectus Femoris Muscle Thickness Strongly Predict Neutropenia in Cancer Patients Receiving Chemotherapy.

Gürkan Güner, Levent Özçakar, Yusuf Baytar, Mehmet Ruhi Onur, Metin Demir, Burak Yasin Aktaş, Oktay Halit Aktepe, Deniz Can Güven, Hakan Taban, Hasan Çağrı Yıldırım and 4 more

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Sarcopenia in glioblastoma: pick up the probe and ditch the tomography.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024
    Article
  6. Article
  7. Evaluating sarcopenia in cancer patients: focus on the rectus femoris muscle.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gürkan GünerDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.
Levent ÖzçakarDepartment of Physical and Rehabilitation Medicine, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey.ORCID 0000-0002-2713-4071
Yusuf BaytarDepartment of Radiology, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey.
Mehmet Ruhi OnurDepartment of Radiology, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey.ORCID 0000-0003-1732-7862
Metin DemirDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.
Burak Yasin AktaşDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.ORCID 0000-0001-5460-4895
Oktay Halit AktepeDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.
Deniz Can GüvenDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.ORCID 0000-0002-6924-9467
Hakan TabanDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.
Hasan Çağrı YıldırımDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.ORCID 0000-0003-3060-377X
Serkan AkınDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.ORCID 0000-0002-7542-9229
Sercan AksoyDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.
Murat KaraDepartment of Physical and Rehabilitation Medicine, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey.
Ömer DizdarDepartment of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06230, Turkey.ORCID 0000-0003-0911-9078

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study was to explore the possible association between low skeletal muscle mass (SMM)-assessed by computed tomography (CT) and ultrasound (US)-and hematologic toxicity in cancer patients. A prospective cohort study was conducted in cancer patients who received anthracycline-based chemotherapy between 2018 and 2020 and who had baseline abdominal CT including L3 level for measuring SMM. Regional muscle measurements were carried out using US. A total of 65 patients (14 males, 51 females) were included. ROC (receiver operating characteristic) analysis identified threshold values of 18.0 mm [AUC (area under the curve) = 0.765] for females and 20.0 mm (AUC = 0.813) for males, predicting severe neutropenia. Using these cut-offs, females with low rectus femoris (RF) thickness (<18.0 mm) had a significantly higher incidence of grade ≥3 neutropenia (50.0% vs. 10.8%,

Indexed as

malignancyskeletal muscle masstoxicitytreatmentultrasound

Identifiers

PMID38473418
PMCPMC10930705

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.